11beta-HSD1 Inhibitors for Metabolic Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new and improved drugs that inhibit 11β-HSD1, as existing inhibitors may not be effective enough in treating conditions related to glucocorticoid-related disorders such as obesity, metabolic syndrome, and hypertension.
Innovation Solution
Development of novel compounds that act as effective inhibitors of 11β-HSD1, specifically pyridyl, pyridazinyl, pyrimidinyl, pyrazolyl, or thiazolyl derivatives, which are designed to inhibit the enzyme's activity and are used in pharmaceutical compositions to treat diseases associated with 11β-HSD1 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing inhibitors are used to treat glucocorticoid-related disorders, then some therapeutic effect is achieved, but the effectiveness is insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structure parameters of the inhibitor molecules. The core structure features (heterocyclic rings, substituent positions, molecular weight, hydrophobicity) are optimized to enhance binding affinity to 11β-HSD1 while improving metabolic stability and oral bioavailability, thereby increasing therapeutic effectiveness
Solution Approach 2:
The patent employs composite molecular structures combining multiple functional groups and heterocyclic systems. The inhibitors feature composite architectures with core heterocyclic rings (pyridine, pyrimidine, thiazole, etc.) combined with various substituents including aryl groups, alkyl chains, and heteroatom-containing moieties, creating molecules with enhanced and balanced pharmacological properties
2Reliability
If 11β-HSD1 activity is inhibited to reduce glucocorticoid levels, then metabolic conditions improve, but potential side effects may arise
Solution Approach 1:
The patent applies local quality by designing inhibitors with selective tissue distribution properties. The molecular structures are optimized to concentrate inhibition in metabolically active tissues (adipose tissue, liver) where 11β-HSD1 overexpression occurs, while minimizing exposure in other organs. This is achieved through specific hydrophobicity parameters and metabolic stability features that guide tissue-selective drug action
Solution Approach 2:
The patent incorporates feedback mechanisms through the design of inhibitors with appropriate pharmacokinetic profiles. The molecules are structured to achieve sustained but controlled inhibition levels, allowing the body's regulatory systems to maintain homeostasis. The feedback is embedded in the drug's metabolism and elimination characteristics, preventing excessive or prolonged inhibition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel compounds effectively inhibit 11β-HSD1, providing potential benefits in treating conditions like obesity, metabolic syndrome, hypertension, and other glucocorticoid-related disorders by reducing glucocorticoid levels, thereby improving insulin sensitivity and glucose tolerance.
Implementation Method 1
The compounds of the invention or pharmaceutically acceptable salts thereof, are effective inhibitors of 11β-HSD1
Data Source
AI summary
This invention relates to novel compounds of the Formula I, Ik, Iq1-21, Ir1-21, Is1-21, It1-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 ß-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.